Hemostasis composition with stable drug effect

A composition and efficacy technology, applied in the field of hemostatic compositions, can solve the problems of enhanced inflammatory response, difficult absorption, delayed wound healing, etc., and achieve the effects of degrading absorption, strong biocompatibility, and promoting wound healing.

Inactive Publication Date: 2017-12-01
冯威
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The domestic products Yixuezhi and instant hemostasis are relatively slow, neither can achieve a good hemostatic effect, and have no positive effect on wound infection and healing
In addition, there are soluble hemostatic gauze Surgicel and carboxymethyl cellulose produced by Johnson & Johnson from abroad. In addition to being difficult to absorb, the highly acidic chemical environment produced by it can easily cause nerve damage, enhance the inflammatory response around the damaged tissue, and cause wound damage. Delayed healing, should not be used widely
[0006] There are many hemostatic drugs on the market now, their efficacy and action time are different, and their efficacy is not fixed for different people, so how to solve the problem of stable efficacy of hemostasis and realize the current one of the puzzles

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hemostasis composition with stable drug effect

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Embodiment 1 (preparation one)

[0024] Choose: 10 parts by weight of starch solution, starch solution comprises the composition of pullulan, carboxymethyl starch and distilled water, starch solution comprises the composition of the pullulan of 20 parts by weight, the carboxymethyl starch of 10 parts by weight and the distilled water of 300 parts by weight ;

[0025] 5 parts by weight of coagulation factor solution, the coagulation factor solution is a mixed solution of activated coagulation factor VII (FAIIa) and coagulation factor X (FX), and the coagulation factor solution includes 1-20 μm of FAIIa and 5-400 μm of FX;

[0026] 5 parts by weight of blood coagulation amino acid solution, the blood coagulation amino acid solution is ε-polylysine solution, and the blood coagulation amino acid solution includes 40 parts by weight of ε-polylysine;

[0027] Chitosan 10 weight parts, chitosan comprises the chitosan dilute solution of weight part 35;

[0028] 5 parts by wei...

Embodiment 2

[0033] Embodiment 2 (preparation two)

[0034] Select: 20 parts by weight of starch solution, starch solution comprises amylopectin, carboxymethyl starch and distilled water, starch solution comprises 20 parts by weight of amylopectin, carboxymethyl starch of 10 parts by weight and distilled water of 300 parts by weight ;

[0035] 7 parts by weight of coagulation factor solution, the coagulation factor solution is a mixed solution of activated coagulation factor VII (FAIIa) and coagulation factor X (FX), and the coagulation factor solution includes FAIIa of 1-20 μm and FX of 5-400 μm;

[0036] 6 parts by weight of blood coagulation amino acid solution, the blood coagulation amino acid solution is ε-polylysine solution, and the blood coagulation amino acid solution includes 40 parts by weight of ε-polylysine;

[0037] Chitosan 15 weight parts, chitosan comprises the chitosan dilute solution of weight part 35;

[0038] 8 parts by weight of the water-soluble polymer auxiliary m...

Embodiment 3

[0043] Embodiment 3 (biological experiment)

[0044] Experiment preparation

[0045] First, forty mice were prepared and fed for ten days under the same conditions to prepare the hemostatic compositions in Example 1 and Example 2, which were respectively experimental group 1 and experimental group 2, and then selected common hemostatic compositions on the market, Mark the control group, allocate ten mice to each of the above three groups, and the remaining ten mice are the blank control group.

[0046] conduct experiment

[0047] First, the mice were fed under the same conditions, and then the mice were scratched at the same position on the back, with the same wound size and length;

[0048] The mice in the experimental group, the experimental group 2 and the control group applied medicine to the wound in the morning and evening respectively, with the same amount of medicine applied;

[0049] Observation records, recorded once a day, the records are as follows:

[0050] ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a hemostasis composition with stable drug effect. The composition is prepared from, by weight, 2-50 parts of starch solution, 0.5-10 parts of blood coagulation factor solution, 1-10 parts of blood coagulation amino acid solution, 3-25 parts of chitosan, 1-10 parts of water-soluble polymer ingredients, 0.5-10 parts of penetration enhancer, 0.5-10 parts of poloxamer, and 10-500 parts of distilled water. The hemostasis composition has stable hemostasis effect, and can guarantee that blood of the wound can be stably and rapidly stopped; the composition is strong in biocompatibility, and able to prevent organization sticking, effectively promote the wound healing and realize the composition degradation and absorption; besides, the hemostasis composition has anti-bacterial function and can guarantee the stability of the hemostasis effect.

Description

technical field [0001] The invention relates to a hemostatic composition, in particular to a hemostatic composition with stable drug effect. Background technique [0002] When bleeding is dealt with in a certain way, quickly stopping the blood from flowing outward is called hemostasis. Hemostatic effects vary from person to person. Some people are fast, some people are slow, and it is related to platelets. [0003] Under normal circumstances, bleeding caused by damage to small blood vessels will stop on its own within a few minutes. This phenomenon is called physiological hemostasis. Physiological hemostasis is one of the important protective mechanisms of the body and is the result of the interaction of various factors and mechanisms. The process of hemostasis mainly includes three processes of vasoconstriction, platelet thrombus formation and blood coagulation. [0004] The hemostatic function of the normal human body can only work on slow and small amounts of bleeding...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61L15/28A61L15/32A61L15/26A61L15/40A61L15/44
CPCA61L15/26A61L15/28A61L15/32A61L15/40A61L15/44A61L2400/04C08L3/02C08L5/08C08L89/00C08L71/02
Inventor 冯威
Owner 冯威
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap